Survey: The Rocky Road to Value-Based Care

Health care leaders resist full commitment


A new industry survey from HealthLeaders Media outlines the top challenges providers are facing in the transition to value-based care. This transition is significant both for the magnitude of the task and for health care leaders’ reluctance to make a full commitment to change, the survey results suggest.

Among the top challenges that health care leaders reported was physician alignment. And a top method for organizations to fuel financial growth was the expansion of outpatient services.

Of the 471 organizations surveyed, 35% said they have pilot efforts under way intended to help them make the transition from fee-for-service to providing value-based care. Another 27% had completed pilots or were in a rollout phase.

Nearly two thirds (65%) of the organizations expected to begin or to increase investment in patient experience improvements over the next three years –– an increase over the 51% logged last year. Overall, 16% of health care leaders expected their organizations to begin or increase investment in actuarial resources, a pivotal activity for those considering risk-based payments.

Nearly half (48%) expected that their organizations would achieve positive financial results in their current fiscal year, and another 9% said they expected strongly positive financial results.

More than one-quarter (28%) of health care leaders said that clinical information technology (IT) is the number one area of IT in strategic importance in supporting their pursuit of financial targets over the next three years. A similar share, 25%, said electronic health record (EHR) interoperability is number one.

Although only 11% said that data-driven knowledge of patient health factors was the number one IT area of strategic importance, 52% included data-driven patient knowledge among their top three.

Source: HealthLeaders Media(link is external); January 14, 2016.

More Headlines

Researchers find potentially “druggable” targets
Opdivo expected to supersede Avastin as standard of care for recurrent disease
Authorities suspend further studies of cannabinoid drug
High cost-to-benefit ratio will limit acceptance
All-cause mortality rate is 39% over six years
Treatment nearly triples progression-free survival rate


Our most popular topics on